Pine Pharmacy (Pine Pharmacy and Home Care Products Center, Inc.), Williamsville, NY
Is Pine Pharmacy (Pine Pharmacy and Home Care Products Center, Inc.) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Pine Pharmacy (Pine Pharmacy and Home Care Products Center, Inc.) hold a New York pharmacy license?
State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. The Colorado State Board of Pharmacy also lists nonresident license OSP 5919 for Pine Pharmacy, Williamsville, NY, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054018087 for PINE PHARMACY AND HOME CARE PRODUCTS CENTER INC, WILLIAMSVILLE, NY, status ACTIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002217 for PINE PHARMACY & HOME CARE PRODUCTS CENTER INC, WILLIAMSVILLE, NY, status ACTIVE (CURRENT), as of Nov 15, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301009954 for Pine Pharmacy and Home Care Products Center Inc, Williamsville, NY, status Active, as of Nov 10, 2026.
Has Pine Pharmacy (Pine Pharmacy and Home Care Products Center, Inc.) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Apr 25, 2019) and 1 FMD-145 letter (Apr 25, 2019) for Pine Pharmacy (Pine Pharmacy and Home Care Products Center, Inc.). State board actions: no New York State Education Department action under this exact name and city was found in the New York State Education Department’s list of Board of Regents disciplinary actions against pharmacy establishments (actions dated Jan 14, 1994 to May 19, 2026) on Nov 8, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Pine Pharmacy and Home Care Products Center, Inc.; Pine Pharmacy
- Location
- Williamsville, NY
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Apr 25, 2019
- FDA Data Dashboard inspections
- 2 inspections: 2 OAI; 3 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 27 observations
- State board records
- Not checked (license records); board actions matched: 0
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Pine Pharmacy and Home Care Products Center, Inc., (dba Pine Pharmacy), a 503A facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Apr 25, 2019 | FMD-145 letter | FMD-145 Letter Issued 04/25/2019 | fda.gov |
| Apr 25, 2019 | Warning letter close-out | Warning Letter Close Out Issued 04/25/2019 | Not linked by FDA |
An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Pine Pharmacy and Home Care Products Center, Inc., Williamsville, NY (FEI number 3010285019), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Dec 16, 2013 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs): Official Action Indicated (OAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Official Action Indicated (OAI) | 3010285019 | 858280 |
| Jul 19, 2013 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs): Official Action Indicated (OAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Official Action Indicated (OAI) | 3010285019 | 841175 |
Form 483s FDA has published for this site
- May 19, 2016: Form 483 to Pine Pharmacy and Home Care Products Center, Inc., published Jan 17, 2024. fda.gov
- Jul 23, 2015: Form 483 to Pine Pharmacy and Home Care Products Center, Inc., published Jan 17, 2024. fda.gov
- Jul 11, 2015: Form 483 to Pine Pharmacy and Home Care Products Center, Inc., published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 27 numbered observations in all, across 3 inspections ending Jul 19, 2013 to Apr 18, 2016. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Mar 30, 2016 to Apr 18, 2016: 8 observations
- Firm on the cover
- Pine Pharmacy and Home Care Products Center, Inc., 5110 Main St, Williamsville, NY 14221-5256
- Establishment type on the cover
- Sterile Drug Producer
- FDA district office on the cover
- 158-15 Liberty Avenue Jamaica, NY 11433 {718} 340-7000 Ext:5301 Fax: {718)662-5661
- Matched to this page by
- firm name, city and state on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Protective apparel is not worn as necessary to protect drug products from contamination.
Specifically, the operator's neck area is not fully covered allowing exposed neck skin over the critical ISO 5 laminar flow area where sterile drug products are processed.
On 4/1/16, excessive conversation was observed between REDACTED B4 operators while each was preparing Avastin Inj sterile drug product in an ISO 5 zone.
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
a. The work surfaces, inside the ISO 5 hoods, are not tested for microbial contamination at least daily during periods of production and at the end of operations. This monitoring is only performed REDACTED B4.
b. Environmental monitoring for non-viable particulates is only performed during the REDACTED B4 by an outside vendor.
c. The ISO 7 clean rooms, the ISO· 7 anteroom, and the unclassified surrounding areas are only monitored for air pressure differentials REDACTED B4.
Observation 3
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the storage of in-process materials.
Observation 4
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.
Specifically, you have·not validated the [15). (41 J sterilization process used for your sterile drug products, such as Progesterone in Sesame Oil Inj. within your REDACTED B4. In addition, your REDACTED B4 used to REDACTED B4 sterilize drug products has not been qualified for use.
Observation 5
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Specifically, your firm does not test every sterile drug lot produced for sterility or endotoxins. In addition, you do not perform antimicrobial effectiveness testing for sterile drug products containing preservatives such as Protamine Zinc Insulin Inj.
Observation 6
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically,
a. Sterile REDACTED B4 are prepared for various products from non-sterile ingredients. These REDACTED B4 can be held for up to REDACTED B4 as for REDACTED B4 injection and REDACTED B4 injection. Your firm has not conducted any studies to support the stability/sterility over the time periods that REDACTED B4 are prepared REDACTED B4.
b. Your firm has not tested for sterility over the assigned Beyond Use Date (BUD) for any sterile injectable or sterile ophthalmic except for Avastin lnj. For example, your firm has not conducted any testing to support the BUDs such as 90 days refrigerated for Phenylephrine-Tropicamide injection or 90 days refrigerated for Ascorbic Acid injection. You have no data to assure that the sterility and potency will be maintained over the time period of the BUD.
Observation 7
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.
Specifically, visual checks of sterile injectable drugs for clarity/discoloration or particulates/contaminants are not performed against contrasting backgrounds .
Observation 8
Employees engaged in the processing of a drug product lack the training required to perform their assigned functions.
Specifically, surface samples obtained from the critical ISO 5 surfaces and glove finger tips along with other clean room surfaces are placed on REDACTED B4 plates. They are REDACTED B4 who have not been trained in determining that.
Inspection Dec 10, 2013 to Dec 16, 2013: 9 observations
- Firm on the cover
- , 5110 Main Street Pine Pharmacy and H ome C are P roducts Center, Inc I J I, Williamsville, N Y 1 4221
- FEI number
- 3010285019
- Establishment type on the cover
- Sterile D rug P roducer
- FDA district office on the cover
- 158-15 Liberty Ave. Jamaica, NY 11433
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate des ign to facilit ate operations for its intended u se .
I I
Specifically, your firm lacks adequate environmental monitoring data to support that the capibilities of its cleanroom can maintain ISO 5 (Class 100) conditions at the laminar flow hood (LAFW) an d th e biological safety cabinet (BSC), the ISO 7 (Class 10,000) conditions in the surrounding "buffer" area , and the ISO 7 conditions in the adjoining gowning room (anteroom) and adjoining storage room and the "powder hood" in the ISO 7 anteroom.
Smoke studies were not performed under actual processing conditions to verify that operators and processing equipment do not alter or impede the unidirectional cascade of air from the HE PA filters t o the ISO 5 laminar flow benches where sterile drug products are opened and manipulated, and to the res t ofthe ISO 7 clean room.
Observation 2
I wr
Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.
Specifically, slerile drug products are aseptically manipulated by the cleanroom operators who w ere non-sterile gowns, non-sterile glasses/goggles, non-sterile footwear, non-sterile facial masks, etc. The only apparell that are sterile are the operator's gloves. The operator's face and head are not fully enclo sed and allows exposed facial skin and hair over the critical ISO 5 laminar flow areas.
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
Specifically, for the newly constructed clean room that became operational on 11/18/2013 and the previous clean room per SOP 7.4 Environmental Monitoring ofthe Clean Room:
a. Environmental monitoring for viable air counts in the ISO 5 zone is only performed REDACTION (b)(4) by an outside contractor .
b. Environmental monitoring for non-viable particulates in the ISO 5 zone is only performed every R E DACTION (b)(4) by an outside contractor.
c. The work surfaces, inside the ISO 5 hoods, are not tested for microbial contamination on frequent basis. Environmental monitoring of the sterile processing area surfaces is performed only REDACTION (b)(4)
Observation 4
The separate or defined areas necessary to prevent contamination or mix-ups are deficient.
Specifically, there are no separate facilities, for processing operations, to prevent contamination from beta-Lactam non-penicillin drugs, such as Ceftazidime ophthalmic drops or Ceftazidime Intravitreal Injection. This beta-Lactam powder, which is contained in glass vials, is processed in the same ISO 5 hoods as sterile non beta-Lactam drugs. There is no assurance that a potential breakage of the glass vial and conse quent powder spill would not contaminate other sterile dru g products.
Observation 5
Equipment and utensils are not sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, non-sterile wipes are either s prayed w it REDACTION (b)(4) to disinfect the ISO 5 hood sterile processing surfaces.
Observation 6
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically, your firm has distributed approximately REDACTION (b)(4) orders, from lots processed in 2 013. For the sterile drug products, the following testing was not performed:
a Assay or product identification testing is not done for all of the sterile injectable or sterile ophthalmic drug products produced.
b. Sterility testing for all drug products produced is not performed. Your firm performs sterility testing in certain cases, as for A vastin syringes.
c. Endotoxin testing data is not available for almost all sterile drug products produced. Some sterile products such as Methylobalamin vials are tested for endotoxins.
d. There is no antimicrobial effectiveness testing data for sterile drug products containing pr servatives, such as fluphenazine and protamine zinc insulin injectable.
Observation 7
An adequate number of batches of each drug product are not tested nor are records ofsuch data maintained to determine a n appropriate expiration date.
Specifically, you produce injectable drug products, sterile ophthalmic solutions and other drug products. The beyond use dates assigned to the drug products are not supported by stability studies coducted by your firm. There is no assurance, with the lack ofappropriate scientific data, that your sterile drug products will remain sterile or maintain potency throughout the expiry period. You solely rely on published literature or vendor supplied information to establish beyond use dates. Examples are Avastin in BD Tuburculin Syringes for 180 days refrigerated and Methylcobalamin in 0.3ml short needle (BD) fo r 90 days.
Observation 8
Results of stability testing are not used in determining expiration dates
Specifically, prescription #REDACTION (b)(6) for Cyclosporin 1% Ophthalmic, sterile veterinary dru g the processing record shows an ingredien t used-Adjuvants Stock for Cyclosporin (a) ey e drop wi th an expiration date of 12/24/13. The Beyond Use Date assigned to this prescription order w as for 18 0 days to March 2, 2014 which is over two months past the expiration date of the aforementioned ingr edient used in preparing this order.
Observation 9
Employees are not given training in the particular operations they perform as part of their function.
Specifically, surface samples of the ISO 5 LAFW and BSC along with other clean room surfaces are placed onto contact plates. Also, gloved fingertip samples are also placed onto the agar surface of the c ontact plate. CFUs are subsequently read by the firm's personnel who have not been trained in d etermining that nor is there any written procedure on how to perform it.
Inspection Jul 16, 2013 to Jul 19, 2013: 10 observations
- Firm on the cover
- , Pine Pharmacy and Home Care Products Center , Inc. 5110 Main Street, Williamsville, NY 14221
- FEI number
- 3010285019
- Establishment type on the cover
- Sterile D rug P roducer
- FDA district office on the cover
- 158-1 5 L iberty A ve. Ja maica, NY 114 33
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Equipment used in the manufacture, processing, packing or holding of drug products is not ofappropriate design to facilitate operations for its intended use and cleaning and maintenance.
Specifically, your firm lacks adequate environmental monitoring data to support that the capabilities of its cleanroom can maintain ISO 5 (Class 1 00) conditions at the laminar flow hood, the ISO 7 (Class 10,000) conditions in the surrounding "buffer" area, and the ISO 8 (Class 1 00,000) conditions in the adjoining gowning room (anteroom) given the following design limitations and practices.
a. Smoke studies were not perfmmed under dynamic conditions to verify that operators and processing equipment do not alter or impede the unidirectional cascade of air from the HEPA filters to the ISO 5 laminar flow bench where sterile drug products are opened and manipulated, and to the rest ofthe ISO 7 clean room.
b. The entry way to the ISO 7 buffer room from the ISO 8 anteroom is through vinyl strip door curtains which do not cover approximately two (2) feet at the bottom ofthe entrance doorway.
c. ...
Observation 2
Clothing of personnel engaged in the processing o fdmg products is not appropriate for the duties they perform.
Specifically,
The non-sterile gowning worn by employees entering the ISO 7 cleanroom is stored in the ISO 8 anteroom in an open plastic bag.
Non-sterile masks and non-sterile bonnets are used to cover the mouth and head of operators during s terile processing; allowing exposed facial skin over the critical ISO 5 laminar flow bench. Additionally, n o goggles are used by those operators.
Observation 3
Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not established.
Specifically,
a. The work surfaces, inside the ISO 5 hood, are not tested for microbial contamination on a frequent basis. Environmental monitoring of the sterile processing area js performed by an outside contractor only every REDACTED (b)(4) by swabbi ng the surfaces. You claim that your firm perfor med this as well without stating the frequency; however you refused to provide documentation to support your claims.
b. Environmental monitoring for viable air counts in the ISO 5 zone is only performed REDACTED (b)(4) by an outside contractor. You claim that your firm performed this as well without stating the frequency; however you refused to provide documentation to support your claims
c. Environmental monitoring for non-viable particulates in the ISO 5 zone is only performed every REDACTED (b)(4) by an outside contractor. You claim that your firm performed this as well without stating the frequency; however you refused to provide documentation to support your claims.
OAT E lSSUED
Observation 4
occurs Adequate exhaust systems or other systems to control contaminants are lacking in areas where air contamination occurs during production.
Specifically, the wall motmted Magnehelic Pressure Gauge, measuring the air pressure from the ISO 8 anteroom to the unclassified surrounding area, was registering at almost zero.
Observation 5
The separate or defined areas necessary to prevent contamination or mix-ups are deficient.
Specifically, there are no separate facilities for processing operations to prevent contamination from beta-Lactam non-penicillin drugs, such as Ceftazidime ophthalmic drops. This beta-Lactam powder, which is contained in glass vials, is processed in the same ISO 5 hood as sterile non beta-Lactam drugs. You refused to provide your written procedures on how to clean a potential breakage of the glass vial and consequent powder spill.
Observation 6
Equipment and utensils are not sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifi cally, non-sterile wipes are either sprayed with REDACTED
(b)(4) to disinfect the ISO 5 hood s terile processing surfaces.
Observation 7
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically, your firm has distributed approximately REDACTED (b)(4) orders, from lots processed in the past year. For the sterile drug products, the following testing was not performed:
a. There were no records provided upon our request to show assay or product identification testing for a ny of the sterile injectable or sterile ophthalmic drug products produced.
b. Sterility testing for all drug products produced is not performed. Your firm claims to perform sterility testing in certain cases, however, no records were provided to us upon request. Additionally, the sterility test method that you stated is utilized, REDACTED (b)(4), has not been validated.
c. Endotoxin testing data is not avail able for any lot of sterile drug products produced. No records were provided to us upon our request.
d. There is no antimicrobial effectiveness testing data for sterile drug products containing preservatives, such as fluphenazine and protamine zinc insulin injectables.
Observation 8
An adequate number of batches of each drug product are not tested nor are records ofsuch data maintained to determine an appropriate expiration date.
s. Specifically, you produce injectable drug products, sterile ophthalmic solutions and other drug product s. The beyond use dates assigned to the drug products are not supported by stability studies conducted by your firm. There is no assurance, with the lack of appropriate scientific data, that your sterile dru g products will remain sterile or maintain potency throughout the expiry period. You solely rely o
n published literature or vendor supplied information to establish beyond use dates up to 30 days fo r sterile drug products.
Observation 9
Procedures designed to prevent microbiological contamination of drug prodncts purporting to be sterile do not include validation of the sterilization process.
Specifically, the aseptic processing of sterile drug products has not been validated. No media
fills/process simulations have been performed. You refused to produce any study reports to show o therwise.
Observation 10
Adequate Jab facilities for testing and approval or rejection ofdrug products are not available to the quality control unit.
Specifically, visual checks of sterile drugs for clarity/discoloration or particulates/contaminants are not performed against a contrasting background.
EM LOYE
State board of pharmacy records
State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. Board actions source.
What this covers: Board of Regents disciplinary actions against pharmacy establishments from the Office of the Professions’ summaries for the pharmacy profession, which start in 1994 (105 of 105 list pages read). These are final Regents actions, mostly consent orders; open complaints and charges not yet decided are not listed. Actions against individual pharmacists are not copied. New York pharmacy licenses and registrations are not checked. Actions in the data are dated Jan 14, 1994 to May 19, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 5919 | OSP | Pine Pharmacy | Williamsville, NY | Active |
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054018087 | LICENSED PHARMACY | PINE PHARMACY AND HOME CARE PRODUCTS CENTER INC | WILLIAMSVILLE, NY | ACTIVE |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0002217 | NONRESIDENT PHARMACY | PINE PHARMACY & HOME CARE PRODUCTS CENTER INC | WILLIAMSVILLE, NY | ACTIVE (CURRENT) |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301009954 | Pharmacy | Pine Pharmacy and Home Care Products Center Inc | Williamsville, NY | Active |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- New York State Education Department disciplinary records
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Michigan Department of Licensing and Regulatory Affairs license file
Records last pulled Nov 15, 2026. Every entry links to the original public record.